Stockreport

Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis [Yahoo! Finance]

Tharimmune, Inc.  (THAR) 
PDF Positive safety/tolerability achieved with TH104 reporting a mild side-effect profile Planning for Phase 2 trial for moderate-to-severe chronic pruritus in primary bi [Read more]